Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer

M. H. Diekstra, A. Fritsch, F. Kanefendt, J. J. Swen, D. J. A. R. Moes, F. Soergel, M. Kinzig, C. Stelzer, D. Schindele, T. Gauler, S. Hauser, D. Houtsma, M. Roessler, B. Moritz, K. Mross, L. Bergmann, E. Oosterwijk, L. A. Kiemeney, H. J. Guchelaar, U. Jaehde*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)604-613
Number of pages10
JournalCPT: Pharmacometrics and Systems Pharmacology
Volume6
Issue number9
DOIs
Publication statusPublished - Sep 2017

Keywords

  • RENAL-CELL CARCINOMA
  • ENDOTHELIAL GROWTH-FACTOR
  • SINGLE-NUCLEOTIDE POLYMORPHISMS
  • 1ST-LINE SUNITINIB
  • METABOLITE SU12662
  • HEALTHY-VOLUNTEERS
  • ACTIVE METABOLITE
  • INTERFERON-ALPHA
  • SU11248
  • BIOMARKER

Cite this

Diekstra, M. H., Fritsch, A., Kanefendt, F., Swen, J. J., Moes, D. J. A. R., Soergel, F., Kinzig, M., Stelzer, C., Schindele, D., Gauler, T., Hauser, S., Houtsma, D., Roessler, M., Moritz, B., Mross, K., Bergmann, L., Oosterwijk, E., Kiemeney, L. A., Guchelaar, H. J., & Jaehde, U. (2017). Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer. CPT: Pharmacometrics and Systems Pharmacology, 6(9), 604-613. https://doi.org/10.1002/psp4.12210